CIBC Asset Management Inc Has $2.01 Million Position in Illumina, Inc. $ILMN

CIBC Asset Management Inc cut its position in Illumina, Inc. (NASDAQ:ILMN) by 21.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,350 shares of the life sciences company’s stock after selling 4,133 shares during the quarter. CIBC Asset Management Inc’s holdings in Illumina were worth $2,013,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ILMN. Elyxium Wealth LLC bought a new stake in shares of Illumina in the fourth quarter valued at about $25,000. Creative Capital Management Investments LLC grew its stake in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. Board of the Pension Protection Fund bought a new position in Illumina during the fourth quarter worth about $26,000. TD Waterhouse Canada Inc. bought a new position in Illumina during the fourth quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Illumina in the 4th quarter worth about $26,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ILMN shares. Evercore reissued an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Piper Sandler dropped their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. raised their price objective on Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $138.38.

Illumina Stock Performance

NASDAQ ILMN opened at $158.04 on Tuesday. The firm’s 50 day simple moving average is $138.43 and its 200 day simple moving average is $133.92. The firm has a market capitalization of $23.91 billion, a price-to-earnings ratio of 28.73, a P/E/G ratio of 3.04 and a beta of 1.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 1 year low of $82.60 and a 1 year high of $177.22.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business earned $0.97 earnings per share. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares in the company, valued at $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,002,371 shares of company stock worth $155,472,900 over the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.